GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2’ -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRVRp51 and has a high genetic barrier against the emergence of resistant variants

Nicole S. Delino, Manabu Aoki, Hironori Hayashi, Shin-ichiro Hattori, Simon B. Chang, Yuki Takamatsu, Cuthbert D. Martyr, Debananda Das, Arun K. Ghosh, Hiroaki Mitsuya
  • Antimicrobial Agents and Chemotherapy, February 2018, ASM Journals
  • DOI: 10.1128/aac.02060-17
The author haven't yet claimed this publicationThe author haven't yet claimed this publication

In partnership with: